Very small embryonic-like stem cells (VSELs) in adult mouse uterine perimetrium and myometrium

Deepa Bhartiya* and Kreema James

Abstract

We have earlier reported the presence of very small embryonic-like stem cells (VSELs) in adult mouse uterus along with slightly bigger progenitors termed endometrial stem cells (EnSCs) and their regulation by ovarian hormones thus demonstrating a crucial role played by them during proliferation, differentiation and remodeling of the endometrium. Present study is a brief communication wherein we have examined the effect of higher dose of estrogen (E, 2 \( \mu \)g/day), progesterone (P, 1 mg/day) and follicle stimulating hormone (FSH, 5 IU/day for 5 days) specifically on the myometrium and perimetrium surrounding the endometrium in bilaterally ovariectomized mice. Similar treatment with E & P was recently used in a study published in the journal Nature to study the effect of steroid hormones on hematopoietic stem cells and this treatment regimen helps achieve hormone levels observed during pregnancy. Quiescent spherical stem cells (lacking PCNA expression) with high nucleo-cytoplasmic ratio and nuclear OCT-4A were detected in the perimetrium of atrophied (bilaterally ovariectomized) uterus. PCNA expression was observed after treatment and cells with cytoplasmic OCT-4B were invariably observed in the myometrium. VSELs were clearly visualized after treatment and the effect of P and FSH was more prominent compared to E on the development of myometrium. It is speculated that stem cells with nuclear OCT-4A located in the perimetrium differentiate to give rise to endothelial and myometrial cells with cytoplasmic OCT-4B. Based on the results of present study and published reports showing the presence of pluripotent markers (OCT-4, NANOG and SOX2) in human myometrial side population and expression of particularly OCT-4A in human leiomyomas, we speculate that these nuclear OCT-4 positive stem cells located in the perimetrium are the possible tumor initiating cells leading to the development of leiomyomas rather than the mesenchymal cells which express cytoplasmic OCT-4B.

Keywords: Uterus, Myometrium, VSELs, Leiomyomas, Hormones

Introduction

Recent published data suggests the existence of a primitive and pluripotent population of stem cells termed ‘very small embryonic-like stem cells’ (VSELs) in various adult organs which express pluripotent and primordial germ cells specific markers and exhibit the ability to expand and differentiate into all three germ layers and also give rise to HSCs and germ cells in vitro [1–4]. Nakada et al. [5] studied the effect of estrogen (2 \( \mu \)g/day) and progesterone (1 mg/day) treatment for 7 days on the hematopoietic stem cells (HSCs) and reported that estrogen promotes expansion of bone marrow HSCs selectively in females. They neither sensitized the mice with low dose of estrogen nor used physiological dose of steroids for their study as is usually done to study the effect of hormones on the uterus [6]. In the present study we have investigated the effect of similar higher dose of estradiol and progesterone (which simulate levels achieved during pregnancy) along with FSH (5 IU/day for 5 days) on the mouse uterus. Present study is focused on the effects of treatment on the perimetrium and myometrium. H&E stained uterine sections and immunexpression of proliferation (PCNA) and stem cell (OCT-4) markers were studied. Techniques like Western or qRT-PCR were not used as they will not provide any additional information. These procedures involve homogenizing the
whole uterine tissue and it will not be possible to study specific effects on the uterine myometrium.

Proliferating cell nuclear antigen (PCNA) is a surrogate marker to study mitogenic effect and monoclonal anti-PCNA mouse IgG antibody (P8825, Sigma) was used in the present study to gauge the effect of treatment on proliferation of myometrial and perimetrical cells. Besides we studied whether the treatment affected stem cells activity by immuno-localization of OCT-4. OCT-4 antibody (ab19857, ABCAM, Cambridge, UK, raised from within residues 300 to the C-terminus of human Oct-4) used in the present study allowed identification of both the alternatively spliced isoforms of OCT-4. Nuclear OCT-4A is crucial to maintain pluripotent state and as the cell initiates differentiation, OCT-4 translocates to the cytoplasm (with no biological function) and eventually gets degraded and is lost in differentiated cells [2]. Similar nuclear and cytoplasmic OCT-4 localization (reflecting spliced variants OCT-4A and OCT-4B) in pluripotent and non-pluripotent human primordial germ cells (PGCs) has been reported by others also [7]. They proposed that OCT-4A in PGCs either translocates to the cytoplasm or is attenuated there possibly for degradation as the significance of cytoplasmic OCT-4 is otherwise unknown. Immunohistochemistry using 3,3′-diaminobenzidine (DAB) was carried out on paraffin sections and deposition of brown chromogen in Hematoxylin counterstained sections allowed localization of specific cell types in a morphological context.

Materials and methods
The study was approved by institute stem cells and animal ethics committees. Bilateral ovariectomy was performed...
on 8 weeks old Swiss mice and after 14 days; they were treated with hormones [estrogen (2 \( \mu \)g/day); progesterone (1 mg/Kg) for 7 days or recombinant human FSH (5 IU/day) for 5 days] via subcutaneous injections into the peritoneum for estrogen & progesterone and in the neck region for FSH. These doses of E & P help attain levels similar to those seen during pregnancy [5]. Uterine tissue was collected and appropriately processed for histological studies and immuno-localization for proliferation marker (PCNA) and a stem cell marker (OCT-4). Paraffin blocks

**Fig. 3** Effect of estrogen treatment on mouse uterine myometrium (M) and perimetrium (P). Estrogen treatment also induced growth of the myometrium and perimetrium but (a–b) small islands in the perimetrium observed after P and FSH treatment were not prominent after estrogen treatment. Histological appearance of the cells comprising the perimetrium was very different (appeared more undifferentiated) after E treatment compared to those after P and FSH treatment shown in Fig. 2. (c & d) Myometrium was also poorly organized comprising loosely arranged cells (asterix) compared to that observed after P and FSH treatment (Fig. 2). Scale bar represents 20 \( \mu \)m

**Fig. 4** Immuno-localization of PCNA after treatment with progesterone (a–b) and (c–d) follicle stimulating hormone. PCNA expression was observed in both P and FSH treated mouse perimetrium but was more in P treated sections compared to after FSH treatment. Cells in both perimetrium and myometrium showed positive expression. Note the development of small blood vessels (asterix) lined by a single layer of endothelial cells at peri- and myometrium junction. Excessive non-specific brown color in A is because of endogenous mouse Ig staining since PCNA antibody is monoclonal antibody being used on mouse sections. Scale bar represents 20 \( \mu \)m
were prepared; sections were cut and stained with Hematoxylin & Eosin (H&E) using standard protocols. Sections were viewed and representative areas were recorded using NIKON 90i Bright-field microscope.

**Immuno-histochemical localization of OCT-4 and PCNA**

Briefly, the paraffin embedded uterine tissue sections were deparaffinized and incubated in xylene for 30 mins after air drying slides were incubated with 3% hydrogen peroxide (Qualigens, India) in 100% methanol for 30 mins in dark after which the sections were gradually hydrated in descending series of methanol to tap water for 5 min each. This was followed by antigen retrieval by immersing the slides in boiling sodium citrate (SSC, Sigma) buffer at pH 6 for 5 mins. After cooling, the slides were washed with 1X PBS buffer for 5 mins. Permeabilization of the sections was done with 0.3% TritonX-100 in PBS buffer for 10 mins for OCT-4. Blocking was done with 10% normal goat serum for 2 h for OCT-4 antibody raised in rabbit and along with 10% normal horse serum for PCNA antibody raised in mice, followed by incubation with the primary antibody OCT-4 (1:100) and PCNA (1:3000) at 4 °C overnight. Primary antibody was replaced with blocking solution for negative control. Next day slides were washed 3 times with PBS (5 min each wash) and then incubated with respective biotinylated secondary antibody for 30 mins followed by avidin biotin complex formation step for 30 min (Vectorstain Elite ABC kit, Vector Laboratories Inc, California, USA), 3 washes with PBS and then color reaction was done by 3,3’-diaminobenzidine (DAB) (Dako, Carpinteria, CA) solution. Sections were counterstained with hematoxylin, dehydrated, cleared, and mounted.

**Fig. 5** Immuno-localization of PCNA after treatment with progesterone (a–b) and (c–d) follicle stimulating hormone. At higher magnification, nuclear PCNA expression was clearly visualized in cells lodged in the perimetrium. Few single cells along the outer lining were also PCNA positive (arrow). Progesterone treatment resulted in higher expression of PCNA compared to FSH treatment. Whereas cells in the myometrium showed nuclear to cytoplasmic expression of PCNA. Scale bar represents 20 μm.
done using diaminobenzidene (Biogenex, USA). The slides were then counterstained with Hematoxylin, dehydrated and cover slipped. Representative areas were photographed under Nikon 90i microscope and the data was recorded.

Results

Histological studies
Histological studies were carried out to study both myometrium and perimetrium which were visualized as distinct layers in cross-section. Myometrium comprised of smooth muscle cells arranged in a circular manner surrounding the inner endometrium. On the outer side it was covered by the perimetrium (also termed the serosa).

In bilaterally ovariectomized mice, both perimetrium and myometrium of atrophied uterus comprised of poorly differentiated cells (Fig. 1a & b). A large number of spherical cells with minimal cytoplasm were clearly visualized (Fig. 1b). The myometrium appeared more organized after both P and FSH treatment (Fig. 2). The spherical cells observed in ovariectomyed mice sections were not observed after treatment with P and FSH. These results suggest that the spherical stem/progenitors cells observed in the ovariectomyed uterus further proliferate and differentiate into mature cells in response to the treatment. Perimetrical cells were organized as small islands below the outer lining of coelomic epithelium and the myometrium was very conspicuous and comprised of tightly woven myoblasts. Estrogen treatment also induced growth (Fig. 3) but the small islands of cells lining the perimetrium observed after P and FSH treatment were not very prominent in E treated sections. Myometrium was also poorly organized after E treatment compared to after P and FSH treatment and comprised loosely arranged cells (Fig. 3d). Blood capillaries in the junction between perimetrium and myometrium (that were lacking in atrophied uterine sections) became prominent after treatment.

PCNA immuno-localization in uterine myometrium and perimetrium
PCNA expression was observed in both P and FSH treated mouse perimetrium and was relatively more in P treated sections compared to after FSH treatment (Figs. 4 & 5). Minimal expression of PCNA was observed in atrophied uterus (Fig. 1c). However, both P and FSH treatment resulted in nuclear expression of PCNA in cells of both perimetrium and myometrium. PCNA expression was also noted after estrogen treatment in both cells present in the perimetrium and myometrium (Figs. 6 & 7). Single cells lining the perimetrium were prominent and expressed PCNA (Fig. 6 b & c). In the perimetrium, different patterns of cellular expression of PCNA (nuclear as well as cytoplasmic) were visualized. Few cells with spindle shaped nuclei were negative for PCNA expression. At higher magnification, only few cells in the myometrium were positive for PCNA and majority of cells were negative (Fig. 7).

OCT-4 immuno-localization in uterine myometrium and perimetrium
OCT-4 expression was clearly observed in the perimetrium as well as myometrium. OCT-4 expression in uterine sections of atrophied uterus showed an interesting pattern (Fig. 1 d). The atrophied uterine sections were enriched for nuclear to cytoplasmic OCT-4 expressing
stem/progenitor cells. P treatment resulted in increased expression of OCT-4 in both perimetrium and myometrium (Figs. 8 & 9). Interestingly, cells in the perimetrium expressed nuclear OCT-4 (Fig. 8b) whereas in the myometrium, OCT-4 expression was predominantly cytoplasmic (Fig. 8 c & d). At higher magnification, few small spherical cells with nuclear OCT-4A were clearly visualized (Fig. 9). Few blood vessels were visualized in the perimetrium which had spherical cells in their lumen expressing nuclear to cytoplasmic OCT-4 (Fig. 9). OCT-4 expression was also observed in the perimetrium and myometrium after FSH treatment (Figs. 10 & 11). Cells lining the perimetrium (coelomic epithelium) and the perimetrium were positive for nuclear OCT-4 (Fig. 10b). In the myometrium, most of cells showed cytoplasmic expression. Interestingly few spherical cells were observed in the myometrium

Fig. 7 Immuno-localization of PCNA after treatment with estradiol (a-b). At higher magnification, cells expressing PCNA were visualized in the perimetrium. Only few cells in the myometrium were positive for PCNA. Spindle shaped cells in the myometrium (a) were negative for PCNA expression. Scale bar represents 20 μm

Fig. 8 Immuno-localization of OCT-4 in uterine myometrium (M) and perimetrium (P) after treatment with progesterone. OCT-4 expression was clearly observed in the perimetrum as well as myometrium. OCT-4 antibody used in the study detects both cells expressing nuclear OCT-4 (a) as well as cytoplasmic OCT-4 (b). It is intriguing to note that cells in the perimetrium expressed nuclear OCT-4 (b) whereas in the myometrium (c-d) OCT-4 expression was predominantly cytoplasmic. These observations suggest that the pluripotent stem cells in the perimetrum possibly differentiate into the cells of myometrium. Please note the cells migrating from the perimetrum to the myometrium (arrow). Few blood vessels were also observed (asterix). Scale bar represents 20 μm
Fig. 9 Immuno-localization of OCT-4 in uterine myometrium and perimetrium after treatment with P (a-e). At higher magnification, few small spherical cells with nuclear OCT-4 (a) were clearly visualized (arrow). Blood vessels (asterix) were visualized in the perimetrium which had spherical cells in their lumen expressing nuclear OCT-4 (arrow). Scale bar represents 20 μm.

Fig. 10 Immuno-localization of OCT-4 in uterine myometrium and perimetrium after treatment with FSH (a-d). Similar pattern of nuclear and cytoplasmic OCT-4 positive cells in the perimetrium and myometrium were observed as after P treatment. The spherical cells expressing nuclear OCT-4A were clearly visualized at higher magnification (encircled). Also cells lining the perimetrium were positive for OCT-4 (arrow). Scale bar represents 20 μm.
positive for OCT-4 expression (Fig. 10). The spherical cells expressing nuclear OCT-4A were clearly visualized at higher magnification (Fig. 11). Similar expression pattern for OCT-4 was also observed after E treatment (Fig. 12). Blood capillaries were prominent after E treatment and cells lining the perimetrium were positive for nuclear OCT-4 (Fig. 12 b & f). Small nuclear OCT-4 positive cells were observed in the lumen of blood capillaries as well as interspersed among cytoplasmic OCT-4 positive perimetrial/myometrial cells (Fig. 12d, e & g). It was intriguing to note that mesenchymal cells with cytoplasmic OCT-4 (possibly arising by differentiation of nuclear OCT-4 positive cells in the perimetrium) appeared to move down from the perimetrium towards the myometrium (Figs. 7a, 8a, 10a and 12 b & c).

Discussion
Present study provides direct evidence for presence of OCT-4 expressing stem/progenitor cells in the atrophied (bilaterally ovariectomized) uterine perimetrium and myometrium. The cells appear undifferentiated and in a quiescent state as evidenced by marked absence of PCNA expression. Treatment with E, P and FSH resulted in increased expression of PCNA and OCT-4 suggesting an activation of stem cells by the treatment. Coelomic epithelial cells lining the perimetrium expressed nuclear OCT-4 as well as PCNA. Perimetrial cells expressed nuclear OCT-4 whereas cells in the myometrium predominantly expressed cytoplasmic OCT-4. Also a distinct population of nuclear OCT-4 positive VSELs was clearly visualized among the mesenchymal cells expressing cytoplasmic OCT-4 (Fig. 13). Results of the present study suggest that the most primitive, nuclear OCT-4A positive cells in the coelomic epithelium and perimetrium possibly differentiate into myometrial cells with cytoplasmic OCT-4. Use of a higher dose of E & P in the present study made it possible for us to uncover the myometrial stem cells for the first time. We have similarly reported existence of VSELs (with nuclear OCT-4) and the progenitors EnSCs (with cytoplasmic OCT-4) in mouse uterus [8] and also in the gonads reviewed in [3]. Various studies provide evidence in support of pluripotent stem cells in the myometrium but have ended up detecting mesenchymal stem cells which are in
abundance. Our results provide first direct evidence in support of nuclear OCT-4A positive, small, spherical stem cells with minimal cytoplasm in the mouse perimetrium and myometrium. One could also carry out flow cytometry studies to locate VSELs in SP or in myometrial cells suspension for various cell surface markers as LIN-/CD45-/SSEA-4+ and CD133+ in humans and as LIN-/CD45-/SCA-1+ cells in mice, provided care is taken to always spin cells at 3000 rpm during processing for various experiments (otherwise VSELs will invariably get discarded).

We had recently argued [9] that MSCs could not be the elusive uterine stem cells as suggested by Gargett’s group [10]. However, they [11] were not convinced since uterine VSELs have been reported only in one earlier pilot study [8]. Present study provides further direct evidence in support of VSELs in the mouse uterus and their regulation by steroid hormones. Interestingly the results show more significant effect of P and FSH on myometrial stem cells compared to E. However, further studies need to be undertaken to substantiate these findings. Effect of FSH treatment alone on uterine myometrial stem/progenitor cells was indeed striking and FSH receptor expression has been reported on stem cells in the testis, ovary and the hematopoietic system reviewed in [2].

Stem cells in the myometrium are considered crucial for the extraordinary growth of the uterus to accommodate the growing baby. Two major groups have characterized stem cells in the uterine myometrium including Al-Hendy’s and Bulun’s group [12]. Al-Hendy’s group has reported that Stro-1+/CD44+ cells which are CD45-/CD34-/CD31- and express Oct-4, DNMT3 and c-Kit as possible stem cells in human and rat myometrium and also in fibroids by studying cells in myometrial side population [12, 13]. These stem cells reduce in numbers with age and were increased in numbers after E + P and E treatment while P did not show any significant effect. Developmental exposure to endocrine disruptor resulted in expansion of these cells thereby also increased the risk for fibroid formation. While Bulun’s group [14] have reported CD34+/CD49+ cells in myometrial SP which also express KLF4, NANOG, SOX2 and OCT-4 as the possible myometrial stem cells and also tumor initiating cells. Stem cells have been reported in human myometrial side population by others also [15] as a relatively quiescent population with majority of them being in G0 phase with low expression of ER & PR, grow under hypoxic conditions and abundant expression of OCT-4 &
Lupicka et al. [16, 17] have reported presence of pluripotent cells expressing OCT-4, NANOG and SOX2 in all the compartment of bovine uterus including myometrium and also in bovine uterus with adenomyosis. Label retaining cells have been reported in beta-catenin deficient mouse uterine myometrium (degenerative uterus with myometrium replaced by adipose tissue) and they also respond to gonadotropins [18].

Stro-1 is considered best marker for mesenchymal stem cells [19] and Mas et al. [12] mention that the cells they isolate also amplify c-Kit, a marker suggestive of differentiated cells rather than stem cells. Moreover, the primers used by them to amplify OCT-4 are for total OCT-4 and not specific for nuclear OCT-4A. They do not mention whether they failed to amplify other pluripotent markers like NANOG or SOX2 or these markers were not studied. It is evident that Al-Hendy's group has successfully isolated mesenchymal stem cells in the myometrium. Whereas Bulun's group seems to have enriched a more primitive population expressing OCT-4/NANOG/SOX-2/KLF4 suggestive of pluripotent state. However, it is crucial for Bulun's group to demonstrate co-expression of CD34/CD49 with pluripotent markers, otherwise their results could also suggest co-existence of two distinct subpopulations of cells (mesenchymal and pluripotent stem cells). The surface phenotype of CD34+/CD49+ has been earlier described on adipose derived stromal cells by another group [20].

Involvement of VSELs in initiating cancers was suggested for the first time by Ratajczak et al. [21] and recently reviewed [22]. Leiomyomas (also known as myomas or fibroids, benign tumors that arise in the myometrium), are most common tumors in women resulting in hysterectomy. They are monoclonal tumors that arise from stem cells lodged in the uterine myometrium [23, 24], have been associated with MEDI2 mutations and WNT/CTNNB1 pathway is involved in their pathogenesis. Al-Hendy's group [12] suggested that Stro-1/CD44+ progenitor cells in the myometrium are the likely tumor initiating cells. Stro-1 is a marker for mesenchymal stem cells (MSCs) and the big
question remains whether they are stem cells or just stromal cells! The term ‘mesenchymal stem cell’ was coined in late 1980s by Arnold Caplan. He has recently modified the term to ‘medicinal signalling cell’ that are in no ways connected to stem cells. MSCs exist in vitro and arise in vivo from pericytes lining the blood vessels in various organs reviewed in [25]. We have earlier reported that MSCs invariably express cytoplasmic OCT-4. Furthermore, a sub-group of small, spherical cells expressing nuclear OCT-4A exists as a sub-group among MSCs and in both Wharton’s jelly from umbilical cord tissue and in primary cultures of bone marrow [26]. VSELs with nuclear OCT-4 evidently differentiate into mesenchymal stem cells with cytoplasmic OCT-4. Taichman et al. [27] have also reported that VSELs are at top of hierarchy for both mesenchymal and hematopoietic stem cells. Thus in the uterus also, rather than MSCs, it is the VSELs with OCT-4A that most likely expand and form fibroids. Ono et al. [28] reported higher expression of OCT-4A (but not cytoplasmic OCT-4B) in myometrial SP cells isolated from human myometrial tissue from 18 patients undergoing hysterectomy. They had concluded that OCT-4A positive cells could be involved in uterine biology as well as in pathology. Similar to our observations that P had a more prominent effect compared to estrogen on myometrium, available published literature also suggests a crucial role of progesterone pathways in the pathophysiology of uterine fibroids by use of selective progesterone receptor modulators reviewed in [29].

To conclude, the present mouse study reveals the presence of nuclear OCT-4A positive VSELs in the uterine perimetrium and implicates them as possible tumor initiator cells (TICs) rather than mesenchymal cells as suggested by others. A shift in focus towards stem cells for their role in uterine biology and pathology will provide newer therapeutic targets and also deeper understanding of the specific etiology of uterine fibroids. Further studies are required in the area and results need to be confirmed by others working in the field.

Abbreviations
E: Estrogen; FS: Follicle stimulating hormone; OCT-4A: Nuclear transcription factor crucial to define pluripotent state of a cell along with other markers; OCT-4B: Alternatively spliced cytoplasmic OCT-4 with no biological function; P: Progesterone; PCNA: Proliferating cell nuclear antigen; VSELs: Very small embryonic-like stem cells.

Acknowledgements
We thank Dr SM Metkari for the bilateral ovariectomy surgeries performed in the mice at the Animal Experimental Facility and Dr Ranita Ganguly with all the treatments. We also acknowledge core support provided by Indian Council of Medical Research for the study.

Funding
Study was funded by core support provided by Indian Council of Medical Research to the Department.

Availability of data and materials
Not applicable.

Authors’ contributions
DB was involved in design of the study, data interpretation, and manuscript preparation. KJ performed all the experiments and data analysis. Both the authors read and approved the final version of the manuscript.

Authors’ information
DB is affiliated to NIRRH and has reported extensively on VSELs biology. KJ is an MTtech student from Dr D.Y. Patil Biotechnology and Bioinformatics Institute, Pune, India who spent 1 year at NIRRH as part of her course requirement.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Study was approved by the Institute for publication and NIRRH accession number is RA/454/01-2017.

Ethical approval and consent to participate
The study was approved by Institute stem cells and animal ethics committee. The study does not involve any human samples.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 February 2017 Accepted: 6 April 2017
Published online: 24 April 2017

References
1. Ratajczak M, Ratajczak J, Suszyńska M, et al. A novel view of the adult stem cell compartment from the perspective of a quiescent population of very small embryonic-like stem cells. Curr Res. 2017;12:166–78.
2. Bhartiya D, Shaikh A, Anand S, Patel H, Kapoor S, Sriram K, Parte S, Unni S. Endogenous, very small embryonic-like stem cells: critical review, therapeutic potential and a look ahead. Hum Reprod Update. 2016;23(1):41–76.
3. Shaikh A, Anand S, Kapoor S, Ganguly R, Bhartiya D. Bone marrow VSELs exhibit differentiation into three embryonic germ lineages and germ & hematopoietic cells in culture. Stem Cell Rev. 2017. doi: 10.1007/s12015-016-9714-0.
4. Shaikh A, Bhartiya D, Kapoor S, et al. Delineating the effects of 5-fluorouracil and follicle-stimulating hormone on mouse bone marrow stem/progenitor cells. Stem Cell Res Ther. 2016;7(1):59.
5. Nakada D, Oguro H, Levi BP, Ryan N, Kitano A, Sato Y, Takeichi M, Wendt GR, Morrison SJ. Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. Nature. 2014;505(7484):555–8.
6. Milligan SR, Mirembe FM. Intraluminally injected oil induces changes in vascular permeability in the ‘sensitized’ and ‘non-sensitized’ uterus of the mouse. J Reprod Fertil. 1985;74(1):95-104.
7. Gkountela S, Li Z, Vincent JJ, Zhang KX, Chen A, Pellegrini M, Clark AT. The ontogeny of chT+ human primordial germ cells proves to be a resource for human germline reprogramming, imprint erasure and in vitro differentiation. Nat Cell Biol. 2013;15:113–22.
8. Gunjal P, Bhartiya D, Metkari S, Manjramkar D, Patel H. Very small embryonic-like stem cells are the elusive mouse endometrial stem cells—a pilot study. J Ovarian Res. 2015;89.
9. Bhartiya D. An update on endometrial stem cells and progenitors. Hum Reprod Update. 2016;22(4):529–30.
10. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Hum Reprod Update. 2016;22(2):137–63.
11. Gargett CE, Deane JA, Schwab KE. Reply: an update on endometrial stem cells and progenitors by Deepa Bhartiya. Hum Reprod Update. 2016;22(4):530–1.
12. Mas A, Stone L, O’Connor PM, Yang Q, Keven D, Simon C, Walker CL, Al-Hendy A. Developmental exposure to endocrine disruptors expands murine myometrial stem cell compartment as a prerequisite to leiomyoma tumorigenesis. Stem Cells. 2016. doi: 10.1002/stem.2519.
13. Mas A, Nair S, Laknaur A, Siman C, Diamond MP, Al-Hendy A. Stromal CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015;104(1):225–34.
14. Yin P, Ono M, Moravek MB, Coon Sth J, Navarro A, Monsivais D, Dyson MT, Druschitz SA, Malpani SS, Serna VA, Qiang W, Chakravarti D, Kim JJ, Bulun SE. Human uterine leiomyoma stem/progenitor cells expressing CD34 and CD49b initiate tumors in vivo. J Clin Endocrinol Metab. 2015;100(4):E601–6. doi:10.1210/jc.2014-2134.

15. Ono M, Manuyama T, Masuda H, Kajitani T, Nagashima T, Arase T, Ito M, Ohta K, Uchida H, Asada H, Yoshimura Y, Okano H, Matsuoka Y. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A. 2007;104(18):7000–5.

16. Łupicka M, Bodek G, Shipigel N, Elnekave E, Korzekwa A. Identification of pluripotent cells in bovine uterus: in situ and in vitro studies. Reproduction. 2015;149(4):317–27.

17. Łupicka M, Socha B, Szczepańska A, Korzekwa A. Expression of pluripotency markers in the bovine uterus with adenomyosis. Reprod Biol Endocrinol. 2015;13:110.

18. Szotek PP, Chang HL, Zhang L, Preffer F, Dombkowski D, Donahoe PK, Teixeira J. Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells. 2007;25(5):1317–25.

19. Lin G, Liu G, Banie L, Wang G, Ning H, Lue TF, Lin CS. Tissue distribution of mesenchymal stem cell marker Strom-1. Stem Cells Dev. 2011;20(10):1747–52.

20. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol. 2001;189(1):54–63.

21. Ratajczak MZ, Shin DM, Liu R, Malick W, Tarnowski M, Ratajczak J, Kucia M. Epiblast/germ line hypothesis of cancer development revisited: lesson from the presence of Oct-4+ cells in adult tissues. Stem Cell Rev. 2010;6(2):307–16.

22. Bhartiya D, Ganguly R. Do somatic cells de-differentiate/trans-differentiate or VSELs initiate cancer and explain plasticity in adult tissues? J Cancer Stem Cell Res. 2016; 4:e1006. DOI: 10.14343/JCSCR.

23. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5738):1589–92.

24. Bulun SE. Uterine fibroids. N Engl J Med. 2013;369:1344–55.

25. Caplan AI. MSCs: the sentinel and safe-guards of injury. J Cell Physiol. 2016;231(7):1413–6.

26. Bhartiya D. Are mesenchymal cells indeed pluripotent stem cells or just stromal cells? OCT-4 and VSELs biology has led to better understanding. Stem Cells Int. 2013;2013:547501.

27. Taichman RS, Wang Z, Shiozawa Y, Jung Y, Song J, Baldino A, Wang J, Patel LR, Havens AM, Kucia M, et al. Prospective identification and skeletal localization of cells capable of multilineage differentiation in vivo. Stem Cells Dev. 2012;21:1557–70.

28. Ono M, Kajitani T, Uchida H, Arase T, Oda H, Nishikawa-Uchida S, Masuda H, Nagashima T, Yoshimura Y, Manuyama T, OCT4 expression in human uterine myometrial stem/progenitor cells. Hum Reprod. 2010;25(8):3059–67.

29. Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665–86.